Latest news for MEC Co (OTC:MECGF) Stock

MEC Co Ltd is a Japan-based chemical manufacturer. The company mainly develops, manufactures, and sells chemicals to produce printed circuit boards. Products offered by the company include dry film pretreatment, solar mask pretreatment, microetching, metal resist stripping, among others. Its products are used in automobile, smartphone, and computer. MEC also serves customers in Continental Asia, Europe, America's, India, The Middle-East, and North-Africa.

MEC Co Ltd

WIIM

CHSN

Chanson International shares are trading higher after the company announced a $7.272 million public offering of 8,980,251 class A shares at $0.81 per share.

Oppenheimer analyst Michael Wiederhorn maintains Ensign Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>) with a Outperform and raises the price target from $155 to $165.

News

Price Target

Analyst Ratings

ENSG

Oppenheimer Maintains Outperform on Ensign Group, Raises Price Target to $165

U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Monday.
Shares of iTeos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) fell sharply in <a href="https://www.benzinga.com/quote/ITOS/analyst-ratings">today's pre-market trading.</a>
The company announced follow-up interim data from GALAXIES Lung-201.
iTeos Therapeutics shares dipped 13.7% to $14.40 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Vizsla Silver Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VZLA#NASDAQ">VZLA</a>) shares fell 11.4% to $1.94 in pre-market trading. Vizsla Silver announced a $65 million bought deal financing.</li>
<li>Murano Global Investments Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNO#NASDAQ">MRNO</a>) shares tumbled 11.1% to $8.89 in pre-market trading after jumping 36% on Friday.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) shares fell 8.5% to $34.79 in pre-market trading. Upstart announced a proposed private offering of $300,000,000 of convertible senior notes due 2029.</li>
<li>Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) shares dipped 8.2% to $24.60 in pre-market trading after gaining around 5% on Friday.</li>
<li>Hyliion Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HYLN#NYSE">HYLN</a>) shares fell 6.7% to $1.96 in pre-market trading after gaining 8% on Friday. Hyliion Holdings, last week, announced it has been awarded a $15 million + contract by the Office of Naval Research to develop its KARNO generator for Navy ships and stationary power applications.</li>
<li>Instil Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) shares declined 6.1% to $79.40 in pre-market trading. Instil Bio and ImmuneOnco announced a global registrational strategy for PD-l1xvegf bispecific antibody, SYN-2510/IMM2510, in non-small cell lung cancer and triple-negative breast cancer.</li>
<li>Canaan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) fell 5.6% to $1.01 in pre-market trading after jumping 15% on Friday.</li>
<li>Solid Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) shares slipped 3% to $7.70 in pre-market trading after adding around 3% on Friday.</li>
<li>Nova Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVMI#NASDAQ">NVMI</a>) shares fell 3% to $200.64 in pre-market trading.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares slipped 2.4% to $138.10 in pre-market trading amid a drop in the price of Bitcoin. MicroStrategy shares gained over 8% on Friday after the company announced the purchase of 18,300 bitcoin.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40860420/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics">Jim Cramer: &#8216;Hold On&#8217; To Builders FirstSource, &#8216;Here&#8217;s The Problem&#8217; With Viking Therapeutics</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

HYLN

ITOS

MRNO

MSTR

NVMI

SLDB

UPST

VZLA

iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Keybanc analyst Austin Wurschmidt maintains American Healthcares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHR#NYSE">AHR</a>) with a Overweight and raises the price target from $16 to $27.

Keybanc Maintains Overweight on American Healthcares, Raises Price Target to $27

Pathfinder's capabilities are now available via the cloud,&nbsp;giving law enforcement new deployment options to accelerate justice
TYSONS CORNER, Va. and PETAH TIKVA, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>), a global leader in premier Digital Investigative solutions for the public and private sectors, announced today Pathfinder in the Cloud with Amazon Web Services (AWS) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), allowing customers to access Cellebrite's industry-leading investigative analytics solution, Pathfinder, through the secure Amazon Virtual Private Cloud (VPC).
Now available for on-premises and cloud use, Pathfinder drastically reduces the hours investigators and analysts spend on cases because its artificial intelligence (AI) capabilities help to swiftly identify meaningful data and connections across multiple devices. It identifies slang and terms associated with criminal activity and allows investigators to search for and categorize explicit images – lessening the volume of exposure to disturbing imagery and audio. With Optical Character Recognition (OCR), Pathfinder also makes data easily searchable as it scans and converts text from images and devices. Additionally, with Cellebrite Pathfinder's Automated Translation Services, law enforcement agencies can quickly overcome language barriers, gaining rapid access to critical data and insights from digital evidence in multiple languages.

AMZN

CLBT

Cellebrite Enhances Investigative Analytics Solution With Amazon Web Services; Pathfinder's Capabilities Are Now Available Via The Cloud, Giving Law Enforcement New Deployment Options To Accelerate Justice

Merit Medical Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), a global leader of healthcare technology, today announced positive 6-month findings from the randomized arteriovenous (AV) fistula arm of its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial. The data were shown at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) during a FIRST@CIRSE presentation. &nbsp;
WRAPSODY is a cell-impermeable endoprosthesis which is intended to extend long-term vessel patency in dialysis patients. Many patients undergoing dialysis rely on a vascular access site created in the arm called an AV fistula. The maintenance of adequate blood flow through this site is crucial for patient survival.
The AV fistula arm of the WAVE trial enrolled 245 patients at 43 sites. Patients were randomized 1:1 to WRAPSODY or percutaneous transluminal angioplasty (PTA). Target lesion primary patency in patients treated with WRAPSODY was 27 percentage points higher than patients in the PTA cohort (89.8% vs. 62.8%, p&lt;0.0001).1 The proportion of patients who experienced an adverse event was similar between cohorts.2

Biotech

General

MMSI

Merit Medical's WRAPSODY WAVE Trial Demonstrates Patency Vs. Standard Of Care In AV Fistula Patients

KOPN

Kopin Corporation Unveils Next-Generation R15 Drive Board For SXGA FLCoS Microdisplay, Targeting Growing 3D Automated Optical Inspection Market; New Product Offers Smaller Form Factor, Enhanced Software, And Lower Cost

GNLN

Greenlane shares are trading higher after the company announced the launch of a new product line for fentanyl, xylazine, and drink spike detection test strips.

Dorchester Minerals, L.P. (the "Partnership") (NASDAQ-DMLP) announced today that it has entered into two separate agreements to acquire mineral, royalty and overriding royalty interests. &nbsp;
On September 12, 2024, the Partnership entered into a non-taxable contribution and exchange agreement with unrelated third parties to acquire mineral, royalty and overriding royalty interests totaling approximately 14,529 net royalty acres located in 14 counties across New Mexico and Texas. Approximately 65% of the acreage is located in the Delaware Basin with the remaining 35% in the Midland Basin. Cash received by the contributing entities on or after July 1, 2024, will be contributed to the Partnership at closing. The contributing entities will convey their interests to the Partnership in exchange for 6,721,144 common units representing limited partnership interests in Dorchester Minerals, L.P. The acquisition is expected to close on September 30, 2024, subject to customary closing conditions.

DMLP

Dorchester Minerals, L.P. Announces 2 Agreements To Acquire Mineral, Royalty And Overriding Royalty Interests; Financial Terms Not Disclosed

VRAX

Virax Biolabs shares are trading higher after the company announced it extended its existing exclusive distribution agreement with Cosmos Health to market Mpox in real time through its PCR detection kits.

The Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) (the "Company" or "Kroger") announced today that it has extended the expiration date of the previously announced offers to exchange (the "Exchange Offers") any and all outstanding notes (the "ACI Notes") of Albertsons Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) ("ACI"), New Albertsons, L.P., Safeway Inc., Albertson's LLC, Albertsons Safeway LLC and American Stores Company, LLC, as applicable, for up to $7,441,608,000 aggregate principal amount of new notes to be issued by the Company (the "Kroger Notes") and cash. Additionally, Kroger announced today that it has extended the expiration date for the related solicitations of consents (collectively, the "Consent Solicitations") to adopt certain proposed amendments (the "Proposed Amendments") to the indentures (collectively, the "ACI Indentures") governing the ACI Notes, solely with respect to the Unconsented Series (as defined in the Company's press release issued on September 11, 2024). The Company hereby extends such expiration date from 5:00 p.m. New York City time on September 17, 2024 to 5:00 p.m. New York City time on September 23, 2024 (as the same may be further extended, the "Expiration Date").

Kroger Has Extended The Expiration Date For Its Exchange Offers And Consent Solicitations Related To Albertsons Companies Notes Until September 23, 2024

Jefferies analyst Amy Li initiates coverage on Biohaven (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) with a Buy rating and announces Price Target of $57.

Initiation

BHVN

Jefferies Initiates Coverage On Biohaven with Buy Rating, Announces Price Target of $57

Stifel analyst Bradley Canino reiterates Relay Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) with a Buy and maintains $28 price target.

Reiteration

RLAY

Stifel Reiterates Buy on Relay Therapeutics, Maintains $28 Price Target

COSM

Virax Biolabs Extends Existing Exclusive Distribution Agreement To Market Mpox Virus Real-Time PCR Detection Kits With Cosmos Health

DCTH

Delcath Systems Highlights Presentation Of Data At ESMO 2024 Demonstrating Efficacy Of HEPZATO KIT For Metastatic Uveal Melanoma Subgroups

Portfolio includes Safety Strips, Inc.'s low-cost test strip that provides an affordable, reliable way for people to test substances for two of the dangerous adulterants that are exacerbating the growing opioid epidemic
Drink Spike Test strips meet New <a href="https://pr.report/2mo0">California Assembly Bill No 1013</a>, passed July 2024, that requires Clubs and Bars to offer for sale to their customers drug testing devices designed to detect the presence of controlled substances in a drink
Greenlane to leverage its strong distribution, operations, marketing and sales teams to support the brand
BOCA RATON, FL / ACCESSWIRE / September 16, 2024 / Greenlane Holdings, Inc. ("Greenlane" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>), one of the premier global sellers of premium cannabis accessories, child-resistant packaging, and specialty vaporization products, today announced its plans to launch an all-new line of fentanyl, xylazine and drink spike detection test strips under the Safety Strips, Inc. ("Safety Strips") brand of drug test strips. Products will be available to order beginning September 25th via the Company's multiple online retail storefronts, (<a href="https://pr.report/2mo1">vapor.com</a>, <a href="https://pr.report/2mo2">puffitup.com</a>, and <a href="https://pr.report/2mo3">higherstandards.com/</a>) as well as its wholesale portal (<a href="https://pr.report/2mo4">wholesale.greenlane.com</a>). Shipments will commence October 1 st.
In August, Greenlane announced that it has entered into a non-binding letter of intent to be the exclusive distributor in the U.S., of Safety Strips drug detection test strips. Greenlane has been a trusted partner for some of the most successful and well-known cannabis and lifestyle brands, such as Higher Standards, Marley Natural and K.Haring, providing full sales coverage, marketing, warehousing and logistics services.

Greenlane To Launch Fentanyl, Xylazine And Drink Spike Detection Test Strips Product Line

Roth MKM analyst Harry Fong maintains Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) with a Buy and raises the price target from $270 to $290.

Roth MKM Maintains Buy on Progressive, Raises Price Target to $290

BDRX

Biodexa Pharmaceuticals Completes $3M Final Match Payment To Access Remaining $17M CPRIT Grant For Phase 3 Study Of eRapa In Familial Adenomatous Polyposis, CEO Highlights Strategic Milestone

Focus Universal Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) ("Focus" or the "Company"), a provider of patented hardware and software design technologies for Internet of Things (IoT) and 5G, today announced that it has entered into securities purchase agreements with a single institutional investor for the purchase and sale of 3,750,000 shares of common stock in a registered direct offering. The purchase price of each share is $0.32.
The aggregate gross proceeds to the Company are expected to be approximately $1.2 million. The transaction is expected to close on or about September 17, 2024, subject to the satisfaction of customary closing conditions. Proceeds from the offering will be used, in part, to continue to build and launch the new software product platform under Lusher Inc.

Offerings

FCUV

Focus Universal  Announces Pricing Of $1.2M Registered Direct Offering For The Purchase And Sale Of 3,.75M Shares Of Common Stock At A Purchase Price Of $0.32/ Share

CLNN

Clene Granted To Meet In-Person With FDA To Discuss CNM-Au8 Biomarker And Related Clinical And Survival Data

MEC Co

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

MEC Co

News

Latest news for MEC Co (OTC:MECGF) Stock